Helen Fitzsimons

Title: Helen Fitzsimons: Innovator in Neurodegenerative Disease Treatment

Introduction

Helen Fitzsimons is a prominent inventor based in the Bronx, NY. She has made significant contributions to the field of neurobiology, particularly in the treatment of neurodegenerative diseases. With two patents to her name, her work focuses on innovative methods to address critical health challenges.

Latest Patents

Helen Fitzsimons' latest patents include the development of a novel Glutamic Acid Decarboxylase (GAD) chimera and methods of use. This invention relates to unique DNA and protein sequences associated with GAD. Furthermore, it discloses a novel composition and related methods for treating neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and epilepsy. The invention utilizes both viral and non-viral delivery systems to target specific regions of the brain. Notably, it employs an adeno-associated viral vector to deliver a nucleotide sequence encoding a novel GAD to areas of the brain that are overstimulated or disinhibited in various diseases.

Career Highlights

Helen Fitzsimons is currently associated with Neurologix, Inc., where she continues her groundbreaking research. Her work has garnered attention for its potential to revolutionize treatment options for patients suffering from debilitating neurological conditions.

Collaborations

Helen collaborates with Ross Bland, contributing to the advancement of their shared goals in neurobiology and therapeutic development.

Conclusion

Helen Fitzsimons stands out as an innovative inventor dedicated to improving the lives of those affected by neurodegenerative diseases. Her contributions through patents and research are paving the way for new treatment methodologies.